Cargando…
PAPP‐A: a promising therapeutic target for healthy longevity
Pregnancy‐associated plasma protein‐A (PAPP‐A) is a proteolytic enzyme that was discovered to increase local insulin‐like growth factor (IGF) availability for receptor activation through cleavage of inhibitory IGF binding proteins (IGFBPs). Reduced IGF signaling has been associated with increased li...
Autores principales: | Conover, Cheryl A., Oxvig, Claus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334524/ https://www.ncbi.nlm.nih.gov/pubmed/28035757 http://dx.doi.org/10.1111/acel.12564 |
Ejemplares similares
-
Indirect targeting of IGF receptor signaling in vivo by substrate-selective inhibition of PAPP-A proteolytic activity
por: Mikkelsen, Jakob H., et al.
Publicado: (2014) -
SUN-591 PAPP-A Inhibition - a Novel Anti-Obesity Therapeutic Approach
por: Ramakrishna, Akhila, et al.
Publicado: (2020) -
PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma
por: Thomsen, Jacob, et al.
Publicado: (2015) -
The metalloproteinase Papp-aa controls epithelial cell quiescence-proliferation transition
por: Liu, Chengdong, et al.
Publicado: (2020) -
Structure of the proteolytic enzyme PAPP-A with the endogenous inhibitor stanniocalcin-2 reveals its inhibitory mechanism
por: Kobberø, Sara Dam, et al.
Publicado: (2022)